**Name:**

**Phone:**

**E-mail:**

**Source language:** English

**Target language:** Russian

**Domain:** Medicine/ Medical Equipment/Pharmacy

**Amount:** 677 words

**Please make sure to indicate your name (first name and last name), contact phone number and your e-mail.**

**Anda Borisova**

**+371 28161544**

**anda.borisova@gmail.com**

Note! Test translation is free of charge and is not subjet to review reports. In case the test is passed the vendor manager will contact you by e-mail.

|  |  |
| --- | --- |
| **Source** | **Target** |
| **Часть 1. Программное обеспечение** | |
| Alarm limits  Installed\nOptions  Edit\nconfiguration  Copy  Change mode  Support mode  Compliance\ncomp.  Volume Support  Pressure Support  Change patient\ncategory  Insp. times  Adult\nalarm limits  Infant\nalarm limits  Next  Previous  Patient data was successfully copied.  Copying patient data has been cancelled.  Failed to copy patient data:\n- processing data.\n\nPlease wait 30 seconds and try again.  Ventilating in Backup Mode. Change mode or go back to support mode!  The &1 plug-in module is incompatible with the system and will not work properly.  Press  The function you requested will be available in approximately two minutes.  Network protocols are incompatible. Panel will not connect to the network.  This ventilator has Tryout Options installed.\n\nPlease check STATUS for more information\nabout available options and expiry date.  Tryout Options have and\nwill not be available after restart!  Tryout Options have expired and are no longer available.\n\nPlease contact your local dealer for purchasing information.  Control board internal battery depleted. Persistent settings will not work.  Severe internal control node error. Starting with defaults.  Panel EEPROM platform identifier didn't match the actual platform and was updated.  Parameter initialization failure.  Exp. flow measuring error  Exp. flow measuring OK  New date and time: &1, &2:&3:&4  Pressure increase timeout: Reached pressure &1 cmH\x9fO.  Safety valve calibration failed. Tried the following opening pressures [cmH\x9fO] &1 &2 &3 &4 &5  Safety valve did not open: Reached pressure: &1 cmH\x9fO |  |
| **Часть 2. Медицинское оборудование** | |
| A View of the Treatment Room  The treatment room contains a collection of sophisticated medical equipment, most of which will already be familiar to you in some form based on your training and previous experience. The treatment room is equipped with safety door interlocks, which enables beaming on only when the door is closed. Depending on local regulations affecting your site, provision is also made for installation of last man out time delay and audible alarm systems. In preparing for treatment, you shut the safety door as you leave the treatment room, or you activate the last man out time delay or alarm system.  Stand and Gantry  The Stand contains the components that produce the high levels of radio-frequency energy required to generate beams. It also houses a water distribution system, a gas pressurizing system, an air system, and additional power supplies. The gantry is the large curved portion of the machine that contains the radiotherapy beam delivery system. It includes a linear accelerator, a bend magnet, an ion chamber, and other beam generation, monitoring, and adjustment devices. The gantry also supports the imager arms.  Collimator  The collimator has two sets of moveable tungsten blocks called the X and Y jaws. These jaws can be opened and closed, based on specifications in the patient plan, to adjust the size of the beam as it leaves the head of the gantry. |  |
| **Часть 3. Фармацевтика** | |
| **Proof-of-Concept Study (Protocol 3110A1-200-GH, OCRC 33)**  Moxidectin is currently being evaluated at the Onchocerciasis Chemotherapy Research Centre (OCRC) in Hohoe, Ghana in a phase 2, proof-of-concept study (protocol 3110A1-200-GH, OCRC 33). This study is ongoing, however, enrollment has been completed as of 30 June 2008, with a total of 172 subjects.  The study is a randomized, ivermectin-controlled, double-blind, single ascending dose, parallel design, inpatient/outpatient study of 3 dose levels of moxidectin (2 mg, 4 mg, and 8 mg) in adult male and female subjects with different degrees of severity of O. volvulus infection. The primary objective of this study is to determine the safety and tolerability of orally administered moxidectin in adult subjects with O. volvulus infection as measured by the incidence of adverse events (AEs) and clinically significant laboratory test results. A secondary objective is to determine doses that are microfilaricidal and, more important, doses that are macrofilaricidal or macrofilaria-sterilizing. The PK of moxidectin is also determined. |  |